BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Depression (MDD) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for major depressive disorder: 92 (65 sponsors; 20 newly posted in the last 180 days, 11 stopped in the last 180 days; 12 new-entrant sponsors). Momentum score 14.7, rank 44 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 3, Phase 2 23, Phase 3 29, Phase 4 4, N/A 33.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Neurocrine Biosciences NBIX | 6 | P3 5, P4 1 | 0 | 0 |
| Intra-Cellular Therapies, Inc. | 3 | P3 3 | 1 | 1 |
| Janssen Research & Development, LLC | 3 | P3 3 | 0 | 1 |
| Eli Lilly and Company LLY | 3 | P2 1, P3 2 | 2 | 0 |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. new entrant | 2 | P3 2 | 2 | 0 |
| Cybin IRL Limited | 2 | P3 2 | 0 | 0 |
| Definium Therapeutics US, Inc. DFTX | 2 | P3 2 | 0 | 0 |
| Xenon Pharmaceuticals Inc. XENE | 2 | P3 2 | 0 | 2 |
| Axsome Therapeutics, Inc. AXSM | 2 | P4 1, P3 1 | 0 | 0 |
| Bukwang Pharmaceutical new entrant | 1 | P3 1 | 1 | 0 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Senseye, Inc. | 1 | P3 1 | 0 | 0 |
| Sunshine Lake Pharma Co., Ltd. SBFM | 1 | P3 1 | 0 | 0 |
| Takeda TAK | 1 | P3 1 | 0 | 0 |
| Tasly Pharmaceutical Group Co., Ltd | 1 | P3 1 | 0 | 1 |
| Vanda Pharmaceuticals VNDA | 1 | P3 1 | 0 | 0 |
| Alto Neuroscience ANRO | 2 | P2 2 | 0 | 1 |
| Draig Therapeutics Ltd | 2 | P2 2 | 1 | 1 |
| Emobot | 2 | NA 2 | 0 | 1 |
| Ionclinics & Deionic SL | 2 | NA 2 | 1 | 1 |
| Luye Pharma Group Ltd. | 2 | P1 1, P4 1 | 0 | 1 |
| Motif Neurotech, Inc. | 2 | NA 2 | 1 | 0 |
| Psyrin Inc. | 2 | NA 2 | 0 | 0 |
| Seaport Therapeutics SPTX | 2 | P2 2 | 0 | 2 |
| Sichuan Credit Pharmaceutical Co., Ltd. new entrant | 2 | NA 2 | 2 | 1 |
New-entrant sponsors: Chengdu Kanghong Pharmaceutical Group Co., Ltd., Bukwang Pharmaceutical, Sichuan Credit Pharmaceutical Co., Ltd..
Recently stopped trials
- NCT06775379 Xenon Pharmaceuticals Inc. - terminated: See Xenon's September 17, 2026 press release providing an update on its psychiatry clinical program and November 9, 2026 press release annou A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- NCT06470035 Neurovalens Ltd. - withdrawn: The study was withdrawn prior to initiation. No participants were enrolled. Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD)
- NCT03986658 NeuroQore Inc. - withdrawn: Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day
- NCT07307768 Soterix Medical - withdrawn: Funding was not provided Ketamine Biomarker Validation
- NCT05518149 Janssen Research & Development, LLC - terminated: The study was Early Terminated as per Sponsor's decision (communicated to sites on 06Mar2025) A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
- NCT07329673 Qbtech AB - suspended: Enrollment/study activities have been temporarily suspended while the sponsor evaluates internal study priorities and resource allocation. T An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
- NCT06029439 Neumora Therapeutics, Inc. - terminated: NMRA-335140 did not achieve the primary endpoint across three randomized controlled trials. Program discontinued due to lack of efficacy in Study to Assess the Safety and Effectiveness of NMRA-335140-501
- NCT07294924 Kernel - terminated: Terminated due to low enrollment. Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements
- NCT04855747 Levomecor Inc. - terminated: Study REL-1017-302 was terminated early by the Sponsor following the prespecified interim analysis for sample size re-estimation at approxim A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
- NCT06011577 Levomecor Inc. - terminated: Study REL-1017-304 was terminated early by the Sponsor following the prespecified interim analysis for sample size re-estimation conducted i Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
- NCT06635135 Janssen Research & Development, LLC - terminated: Early study termination due to insufficient efficacy. A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depress
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Alto Neuroscience ANRO | NCT05922878 Study of ALTO-300 in MDD | Major Depressive Disorder | recruiting | 325 |
| 2026-12-30 est. | P3 | Janssen Research & Development, LLC | NCT06559306 Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Depressive Disorder, Major | recruiting | 752 |
| 2026-12-31 est. | P1/P2 | Mapi Pharma Ltd. | NCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatmen | Schizophrenia; Bipolar I Disorder; Major Depressive Disorder | recruiting | 24 |
| 2026-12-31 est. | P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT07226661 Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | Major Depressive Disorder (MDD) | recruiting | 230 |
| 2026-12-31 est. | P2/P3 | Tasly Pharmaceutical Group Co., Ltd | NCT07485595 A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression | Depression | not yet recruiting | 180 |
| 2027-01 est. | P3 | Xenon Pharmaceuticals Inc. XENE | NCT06922110 An Open-Label Study of Azetukalner in Major Depressive Disorder | Major Depressive Disorder | active not recruiting | 460 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | Beckley Psytech Limited | NCT05660642 An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression | Treatment Resistant Depression | recruiting | 72 |
| 2026-10-28 | P3 | Xenon Pharmaceuticals Inc. XENE | NCT06775379 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Major Depressive Disorder | terminated | 357 |
| 2026-09-30 est. | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT06958692 A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder | Major Depressive Disorder (MDD) | recruiting | 388 |
| 2026-09-04 | P3 | Cybin IRL Limited | NCT06564818 "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Major Depressive Disorder | completed | 223 |
| 2026-08-17 | P3 | Neumora Therapeutics, Inc. NMRA | NCT06029439 Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Major Depressive Disorder | terminated | 904 |
| 2026-07-30 | P2 | atai Therapeutics, Inc. | NCT06524830 A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Treatment Resistant Depression | completed | 142 |
| 2026-07-27 | P2 | AbbVie ABBV | NCT06236880 A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD | Major Depressive Disorder | completed | 126 |
| 2026-07-14 | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06827431 The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression | Major Depressive Disorder (MDD) | completed | 786 |
| 2026-07-08 | P2 | Sirtsei Pharmaceuticals, Inc. | NCT06254612 A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Major Depressive Disorder | completed | 497 |
| 2026-06-25 | P2 | Hangzhou PhecdaMed Co., Ltd. | NCT07018245 Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder | Depression | completed | 149 |
| 2026-06-25 | P2 | Janssen Research & Development, LLC | NCT06785012 A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Depressive Disorder, Major | completed | 105 |
| 2026-06 est. | P2 | Autobahn Therapeutics, Inc. | NCT06633016 Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Major Depressive Disorder | recruiting | 230 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "major depressive disorder"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.